Investing Profile

Frank Torti

Investor
Vant Chair at Roivant Sciences
United States
Photo of Frank Torti, Investor
Harvard Business School Network
424 CONNECTIONS
New Enterprise Associates (NEA) Network
42 CONNECTIONS
New Enterprise Associates Network
16 CONNECTIONS
cb
Investor
$10K - $50K
$25K
13
CompanyStageDateRound SizeTotal Raised
Annexon Biosciences
Series CJul 2020$100M
Series CDec 2018$75M
Series BJun 2016$44M
$220M
Galera Therapeutics
Series CSep 2018$70M
Series BFeb 2016$5M
Series BOct 2015$37M
Series AAug 2014$5M
Series ADec 2012$11M
$130M
Co-investors: James Barrett
Xoc Pharmaceuticals
Series AFeb 2018$30M
$30M
OrphoMed
Series AMay 2017$39M
$39M
Co-investors: Michael Martin (Takeda Ventures)
Tarveda Therapeutics
Series CJan 2016$38M
$110M
Co-investors: Aymeric Sallin (NanoDimension), James Barrett
CITIC Pharmaceutical
Series DDec 2009$1M
Series CApr 2008$22M
$23M
Co-investors: Nisa Leung (Qiming Venture Partners)
CEO and Chairman Telavant2022 - Present
Vant Chair Roivant Sciences2018 - Present
Partner New Enterprise Associates2007 - 2018
Partner New Enterprise Associates (NEA)2007 - 2018
Harvard Business School MBA
University of North Carolina at Chapel Hill School of Medicine MD